Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year




Total Raised


Date of IPO


About Cypros Pharmaceuticals

Developer of therapeutic drugs for the treatment of disorders involving ischemia (impaired blood flow) such as stroke, traumatic head injury, heart attack, adult respiratory distress syndrome, and sepsis. The company has exclusive rights to two cytotherapeutic drug candidates, one of which is currently in clinical development. The candidate, CPC-111, reactivates anaerobic metabolism, a natural process whereby the life sustaining fuel adenosine triphosphate can be generated in ischemic conditions. The company is also pursuing the development of a new class of neuronal calcium channel blocker and a glial chloride channel blocker. Both drugs are designed to arrest cell damage early to treat the degenerative results of a stroke or injury-induced call trauma.

Cypros Pharmaceuticals Headquarter Location

11211 Sorrento Valley Road

San Diego, California, 92121,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.